TECENTRIQ 1200 MG / 20 ML — DIN 02462990
ATEZOLIZUMAB : 1200 MG / 20 ML · HOFFMANN-LA ROCHE LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is TECENTRIQ?
TECENTRIQ 1200 MG / 20 ML contains ATEZOLIZUMAB : 1200 MG / 20 ML. It is listed in the Health Canada Drug Product Database under DIN 02462990, held by HOFFMANN-LA ROCHE LIMITED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 02-May-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TECENTRIQ used for?
TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated for: First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in combination with carboplatin and etoposide for adult patients; as monotherapy for adjuvant treatment of Stage II to IIIA NSCLC with PD-L1 expression on ≥ 50% of tumour cells, and for first-line treatment of metastatic NSCLC with high PD-L1 expression and no EGFR or ALK genomic tumour aberrations; in combination with bevacizumab, paclitaxel and carboplatin for first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations; in combination with nab-paclitaxel and carboplatin for first-line treatment of adult patients with metastatic non-squamous, non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations; for locally advanced or metastatic NSCLC with progression on or after platinum-based chemotherapy; in combination with bevacizumab for first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy; and in combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression on tumour-infiltrating immune cells (IC) covering ≥ 1% of the tumour area, and who have not received prior chemotherapy for metastatic disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Atezolizumab cost around the world?
Atezolizumab is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 2 | 48 | AUD███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 7 | NOK███.██ |
| Bahrain | retail (max) | 1 | 3 | BHD███.██ |
| Czechia | max producer price (ex-factory) | 1 | 3 | CZK███.██ |
| Greece | producer price (ex-factory) | 3 | 3 | EUR███.██ |
| Hungary | producer price (ex-factory) | 3 | 3 | HUF███.██ |
| Iceland | max wholesale | 1 | 3 | ISK███.██ |
| Italy | ex-factory (classe H) | 3 | 3 | EUR███.██ |
| United Arab Emirates | public | 2 | 2 | AED███.██ |
| Romania | max producer price | 2 | 2 | RON███.██ |
| Slovakia | categorised final price | 2 | 2 | EUR███.██ |
| South Africa | single exit price | 2 | 2 | ZAR███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
82 pack listings across 24 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Atezolizumab pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Atezolizumab in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Atezolizumab — 3 DINs, of which 3 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| HOFFMANN-LA ROCHE LIMITED | 3 | 3 | TECENTRIQ, TECENTRIQ SC | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1200 MG / 20 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 1200 mg/20 mL (60 mg/mL) and 840 mg/14 mL (60 mg/mL) single use vials |
| Storage | If the solution is not used immediately, it can be stored for up to 30 days at 2 - 8°C, or 24 hours at ambient temperature |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Atezolizumab |
|---|---|
| ATC code | L01FF05 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02462990 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2462990 |
| Brand name | TECENTRIQ |
| Generic / active ingredient | ATEZOLIZUMAB : 1200 MG / 20 ML |
| Market authorization holder | HOFFMANN-LA ROCHE LIMITED |
| Health Canada schedule | Prescription |
| ATC code | L01FF05 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01FF |
| Current status | MARKETED |
| Status date | 02-May-2017 |
| Original market date | 2017-05-02 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| TECENTRIQ | 840 MG / 14 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02492393 |
| TECENTRIQ SC | 125 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02546310 |
2 · Same class — other molecules in ATC L01FF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Nivolumab | OPDIVO · OPDIVO SC | 3 | 3 | Yes |
| Atezolizumab | TECENTRIQ · TECENTRIQ SC | 3 | 3 | Yes |
| Cemiplimab | LIBTAYO | 2 | 1 | Yes |
| Pembrolizumab | KEYTRUDA | 2 | 1 | Yes |
| Retifanlimab | ZYNYZ | 1 | 1 | Yes |
| Avelumab | BAVENCIO | 1 | 1 | Yes |
| Dostarlimab | JEMPERLI | 1 | 1 | Yes |
| Durvalumab | IMFINZI | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01F
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01FX | Amivantamab · Belantamab Mafodotin · Blinatumomab · Brentuximab Vedotin · Catumaxomab · +19 more | 36 | 29 |
| L01FD | Pertuzumab · Trastuzumab · Trastuzumab Deruxtecan · Trastuzumab Emtansine | 18 | 16 |
| L01FG | Bevacizumab · Ramucirumab | 14 | 14 |
| L01FA | Obinutuzumab · Ofatumumab · Rituximab | 11 | 8 |
| L01FC | Daratumumab · Isatuximab | 5 | 5 |
| L01FY | Nivolumab And Relatlimab · Pertuzumab And Trastuzumab | 4 | 4 |
| L01FE | Cetuximab · Necitumumab · Panitumumab | 5 | 3 |
| L01FB | Inotuzumab Ozogamicin | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TECENTRIQ called?
Also recorded in Canada as: 20 ML atezolizumab 60 MG/ML Injection [Tecentriq] (US), 14 ML atezolizumab 60 MG/ML Injection [Tecentriq] (US), 15 ML atezolizumab-tqjs 125 MG/ML / hyaluronidase-tqjs 2000 UNT/ML Injection [Tecentriq Hybreza] (US), 20 ML atezolizumab 60 MG/ML Injection (US), 14 ML atezolizumab 60 MG/ML Injection (US), 15 ML atezolizumab-tqjs 125 MG/ML / hyaluronidase-tqjs 2000 UNT/ML Injection (US), ATEZOLIZUMAB (US), ATEZOLIZUMAB AND HYALURONIDASE-TQJS (US), ATEZOLIZUMAB (GLOBAL), ATEZOLIZUMAB-GYPZ (US), ATEZOLIZUMAB (UK).
The same molecule, Atezolizumab, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Tecentriq SC | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.